SDC1 and neoplasm: We demonstrated that all antibody species (WT nBT062, stable nBT062, half nBT062 and bispecific nBT062-natalizumab) were capable of CD138 binding, internalization and, when conjugated to DM4, tumor cell killing in vitro and in vivo.